Close Menu

Gastrointestinal

News on in vitro diagnostics for gastrointestinal disease.

The blood test will be available to specialty and primary care physicians across the US and Canada from LabCorp by early 2021.

The financing round was led by Asian private investment firm AT Capital and early-stage deep-tech venture capital fund Elev8.vc.

The company plans to use the proceeds of the round to fund ongoing development and commercialization of its point-of-care diagnostic platform.

Progenity recently agreed to pay millions to three major insurers under settlement agreements related to allegations over undisclosed past business practices.

The analyzer and assay use immunofluorescent technology to detect H. pylori antigens in human stool and helps eliminate subjectivity.